ATOHSAD981 Treatment for Obesity Hypoventilation Syndrome

This study is a phase 2 trial that explores the effectiveness of a drug called AD981 in treating obesity hypoventilation syndrome, a condition where individuals with obesity have difficulty breathing properly, leading to higher levels of carbon dioxide in the blood. The study focuses on patients who have this condition confirmed through a sleep study (polysomnography) and overnight measurement of carbon dioxide levels through the skin (transcutaneous overnight measurement of CO2). The goal is to find a potential new treatment that could help manage this condition better. In this study, participants receive either AD981 or a placebo, a substance that looks like the drug but has no active ingredients. Neither the participants nor the researchers know who gets which, ensuring the results are unbiased. This is a 'cross-over' study, meaning participants who initially receive the placebo will later receive AD981, and vice versa. The main outcome measured is the change in carbon dioxide levels in the blood overnight, which helps determine if AD981 is effective in managing obesity hypoventilation syndrome.